Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02526212 · ClinicalTrials.gov registry record · Phase 3
Buprenorphine Group Medical Visits in Primary Care
A Phase 3 study of Opioid-Related Disorders, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT02526212: Completed Phase 3 study of Opioid-Related Disorders, sponsored by Montefiore Medical Center.
NCT02526212 is a Phase 3 study of Opioid-Related Disorders that has completed, run by Montefiore Medical Center. The registered enrollment target is 18 participants, below the 347-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02526212, a Phase 3 study of Opioid-Related Disorders, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary goal of this research is to improve the effectiveness of buprenorphine maintenance treatment (BMT) within primary care. Investigators propose that providing BMT as part of a group medical visit (instead of an individual visit) will improve treatment outcomes for patients with persistent opioid abuse, because members become accountable to the group, are exposed to beneficial habits of others (i.e. positive deviance), and can receive efficacious behavioral interventions concomitantly with medical management
Primary Outcome
Opioid abstinence will be based on self-reported opioid use in the prior 30 days at the 8 week visit and the results of urine toxicology test at the 8 week visit. Abstinence (yes) will require no self-reported opioid use and negative urine toxicology test for opiates, methadone, and oxycodone.
Conditions Studied
Interventions
- BEHAVIORAL Treatment as usual
- DRUG Buprenorphine
- BEHAVIORAL G-BMT
Study Locations (1)
New York
- Comprehensive Health Care Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2019-05 |
| Phase | Phase 3 |
What the finished NCT02526212 record still lists
NCT02526212 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 347-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Opioid-Related Disorders appearing as the primary indexed condition, and to 3 interventions - of which Treatment as usual is the first listed.
NCT02526212 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02526212 about?
NCT02526212 is a clinical study titled "Buprenorphine Group Medical Visits in Primary Care". The primary goal of this research is to improve the effectiveness of buprenorphine maintenance treatment (BMT) within primary care. Investigators propose that providing BMT as part of a group medical visit (instead of an individual visit) will improve treatment outcomes for patients with persistent...
What is the current status of trial NCT02526212?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 18 participants. The study started on 2017-01-01. Estimated completion is 2019-05.
What conditions does trial NCT02526212 study?
This clinical trial studies the following conditions: Opioid-Related Disorders.
What interventions are being tested in trial NCT02526212?
The interventions under investigation include: Treatment as usual (BEHAVIORAL), Buprenorphine (DRUG), G-BMT (BEHAVIORAL).
Who is sponsoring clinical trial NCT02526212?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02526212 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02526212's enrollment target sits among peer trials
18 39th of 47 higher than 9 of 47 other Opioid-Related Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid-Related Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
RECRUITING · Phase 3
-
Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence
COMPLETED · Phase 3
-
Medication Treatment for Opioid Use Disorder in Expectant Mothers
COMPLETED · Phase 3
-
Open-Label Treatment Extension Study
COMPLETED · Phase 3
-
Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI